A brain-targeted biomimetic iron-porphyrin covalent organic framework nanoplatform for Alzheimer's disease: synergistic intervention via antioxidant, Aβ-regulating and immunomodulatory effects.
This study presents a novel nanoplatform that targets multiple pathways in Alzheimer's disease, showing promise in animal models without making definitive treatment claims.
Where it sits
this study against the rest of the ghk-cu corpusSummary and findings
This study developed a biomimetic nanoplatform targeting Alzheimer's disease, integrating multiple therapeutic bioactivities. In APP/PS1 transgenic mice, treatment resulted in reduced Aβ plaque deposition and improved cognitive functions. The study reports various in vitro and in vivo effects without making therapeutic claims.
Abstract
The pathological progression of Alzheimer's disease (AD) involves multiple interconnected pathways, including β-amyloid (Aβ) deposition, oxidative stress, and microglial dysfunction, which together form a self-reinforcing vicious cycle. This complexity poses a major challenge to conventional single-target therapeutic strategies. To address this limitation, we developed a biomimetic nanoplatform integrating active brain targeting, multiple therapeutic bioactivities, and immunomodulatory function. The core of this platform was an iron-porphyrin-based covalent organic framework (COF) that possesses enzyme-mimetic antioxidant activity, metal-ion-chelating capability, and Aβ-modulating properties. The COF core was cloaked with a BV2 microglial membrane (BM) to enhance biocompatibility and further functionalized with Angiopep-2 peptide to enable efficient blood brain barrier (BBB) penetration. In vitro studies demonstrated that the platform effectively scavenged various reactive oxygen species, achieved a copper-ion chelation rate of 41.78%, inhibited Aβ aggregation, and depolymerized pre-formed fibrils. At the cellular level, the nanoplatform not only protected neurons from β-amyloid-induced toxicity but also improved the redox status and mitochondrial function of microglia. Furthermore, it promoted the polarization of microglia from the pro-inflammatory M1 phenotype toward the neuroprotective M2 phenotype, which was correlated with enhanced β-amyloid phagocytic capacity. In APP/PS1 (APPswe/PSEN1dE9) transgenic mice, treatment with this nanoplatform markedly reduced cerebral Aβ plaque deposition, attenuated neuroinflammation and oxidative stress, and improved BBB integrity, ultimately leading to the remarkable recovery of spatial learning, memory, and spontaneous exploration abilities in mice. In summary, this integrated nano-strategy, which combines delivery, clearance, and modulation, represents an effective multi-target approach for intervening in the complex pathological network of AD.
Background
This paper addresses the multifactorial nature of Alzheimer's disease (AD), which involves β-amyloid deposition, oxidative stress, and microglial dysfunction. Previous research has highlighted the limitations of single-target therapies in effectively managing AD's complex pathology. The development of a multi-target approach, such as the biomimetic nanoplatform described, is essential for potentially improving therapeutic outcomes in AD.
Methods
The study utilized a biomimetic nanoplatform composed of an iron-porphyrin-based covalent organic framework (COF) cloaked with BV2 microglial membrane and functionalized with Angiopep-2 peptide. The primary outcome measures included Aβ plaque deposition, neuroinflammation, oxidative stress, and cognitive function in APP/PS1 transgenic mice. Not reported in abstract.
Results
The treatment with the nanoplatform led to a marked reduction in cerebral Aβ plaque deposition. Additionally, it attenuated neuroinflammation and oxidative stress while improving BBB integrity. Cognitive abilities, including spatial learning and memory, were notably enhanced in the treated mice.
Interpretation
The findings suggest that the biomimetic nanoplatform may provide a synergistic approach to addressing multiple pathways involved in AD. However, the effect sizes and clinical significance in human populations remain uncertain, given the reliance on animal models. The study's limitations, including potential confounding factors inherent in animal research, may affect the generalizability of the results to human patients.
Key findings
- Copper-ion chelation rate of 41.78%.
- Markedly reduced cerebral Aβ plaque deposition in APP/PS1 mice.
- Improved BBB integrity and enhanced spatial learning and memory in treated mice.
Limitations
- Primarily animal model study, limiting human applicability.
- Not reported in abstract.